Key result
Early lipid-lowering therapy prevents premature cardiovascular complications in pediatric familial hypercholesterolemia.
Why the study?
The optimal screening program for early detection has not been established, and highlighting best therapeutic strategies from early life is needed to prevent premature cardiovascular complications.
Early detection and multidisciplinary treatment, including lifestyle modifications and lipid-lowering medications, are crucial for preventing premature cardiovascular disease in children and adolescents with familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
Supports early multidisciplinary care in pediatric familial hypercholesterolemia; leaves open optimal screening protocols and novel agent durability.
Familial hypercholesterolemia is a common autosomal hereditary disorder characterized by elevated concentrations of low-density lipoprotein cholesterol and the development of premature atherosclerosis and cardiovascular disease. Early diagnosis, as well as prompt and aggressive treatment, are fundamental steps to prevent cardiovascular complications and a high rate of premature mortality in children and adolescents. Clinics and genetics are the two main aspects on which diagnosis is based. Widespread screening programs are a respectable option for the early detection of familial hypercholesterolemia. Different types of screening have been proposed so far; however, the optimal screening program has not yet been found. The treatment approach for both heterozygous and homozygous familial hypercholesterolemia in the pediatric population is multidisciplinary, including lifestyle modifications, standard lipid-lowering medications, and novel pharmacological agents. The latter show promising results, especially for patients who experience intolerance to other treatment or present with more severe conditions. Our purpose is to focus on the importance of the early detection of familial hypercholesterolemia, and to highlight the best therapeutic strategies, including the recent approaches based on current clinical evidence, that need to be adopted from the earliest stages of life.
No takes yet. Share an insight, caveat, or question.
Mainieri et al. (2022) conducted a review in Familial Hypercholesterolemia. Early diagnosis and multidisciplinary treatment, including standard lipid-lowering medications and novel pharmacological agents, are fundamental to prevent premature cardiovascular complications in children and adolescents with familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: